Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 [Recommendations on the use of rituximab for patients with rheumatoid arthritis].

Literature DB >> 18830700

[Recommendations on the use of rituximab for patients with rheumatoid arthritis].

A Rubbert-Roth¹, G Burmester.

Abstract

Entities: Chemical Disease Species

Mesh：

Substances：

Year: 2008 PMID： 18830700 DOI： 10.1007/s00393-008-0348-8

Source DB: PubMed Journal: Z Rheumatol ISSN： 0340-1855 Impact factor: 1.372

× No keyword cloud information.

7 in total

Review 1. [Pharmacotherapy of rheumatoid arthritis].

Authors: E Gromnica-Ihle
Journal: Z Rheumatol Date: 2002 Impact factor: 1.372

2. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks.

Authors: Stanley B Cohen; Paul Emery; Maria W Greenwald; Maxime Dougados; Richard A Furie; Mark C Genovese; Edward C Keystone; James E Loveless; Gerd-Rüdiger Burmester; Matthew W Cravets; Eva W Hessey; Timothy Shaw; Mark C Totoritis
Journal: Arthritis Rheum Date: 2006-09

3. Consensus statement on the use of rituximab in patients with rheumatoid arthritis.

Authors: J S Smolen; E C Keystone; P Emery; F C Breedveld; N Betteridge; G R Burmester; M Dougados; G Ferraccioli; U Jaeger; L Klareskog; T K Kvien; E Martin-Mola; K Pavelka
Journal: Ann Rheum Dis Date: 2006-10-26 Impact factor: 19.103

4. [Revision of the recommendations of the Commission on Pharmacotherapy of the German society for Rheumatology. Therapy with tumour necrosis factor blockers for inflammatory rheumatic illnesses].

Authors: B Manger; H Michels; H G Nüsslein; M Schneider; J Sieper
Journal: Z Rheumatol Date: 2007-02 Impact factor: 1.372

5. The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial.

Authors: Paul Emery; Roy Fleischmann; Anna Filipowicz-Sosnowska; Joy Schechtman; Leszek Szczepanski; Arthur Kavanaugh; Artur J Racewicz; Ronald F van Vollenhoven; Nicole F Li; Sunil Agarwal; Eva W Hessey; Timothy M Shaw
Journal: Arthritis Rheum Date: 2006-05

6. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis.

Authors: Jonathan C W Edwards; Leszek Szczepanski; Jacek Szechinski; Anna Filipowicz-Sosnowska; Paul Emery; David R Close; Randall M Stevens; Tim Shaw
Journal: N Engl J Med Date: 2004-06-17 Impact factor: 91.245

7. Efficacy and safety of rituximab in type II mixed cryoglobulinemia.

Authors: Francesco Zaja; Salvatore De Vita; Cesare Mazzaro; Stefania Sacco; Daniela Damiani; Ginevra De Marchi; Angela Michelutti; Michele Baccarani; Renato Fanin; Gianfranco Ferraccioli
Journal: Blood Date: 2003-01-30 Impact factor: 22.113

7 in total

3 in total